• Biohaven announced it has completed enrollment in a Phase 2 proof-of-concept trial of taldefgrobep alfa, a myostatin-activin pathway inhibitor being tested as a self-administered, dose-ranging monotherapy for overweight and obesity across 20 U.S. sites, with topline data expected in the second half of 2026.
• The program is drawing attention because taldefgrobep alfa aims to deliver high-quality weight loss by reducing fat mass while preserving or increasing lean muscle, a profile that differs from many existing obesity treatments.
• We’ll now examine how this Phase 2 milestone in obesity, and its focus on preserving lean mass, shapes Biohaven’s investment narrative.

Outshine the giants: these 21 early-stage AI stocks could fund your retirement.

What Is Biohaven's Investment Narrative?

To own Biohaven today, you have to believe its broad, high‑spend pipeline can translate into one or two meaningful commercial products before the cash runs thin. The completion of Phase 2 enrollment for taldefgrobep in obesity adds a potentially important upside lever, but it does not change the near‑term picture: the key catalysts still sit with the FDA decision on troriluzole in SCA and upcoming readouts from BHV‑7000 and the MoDE platform. With no revenue, very large annual losses of about US$739,000,000, repeated equity raises and a volatile share price that has fallen sharply over the past year, financing risk remains front and center. This new obesity asset gives the story more long‑term optionality, but it also increases execution and capital needs in an already crowded field.

However, one financing risk in particular is something shareholders should not overlook. The valuation report we've compiled suggests that Biohaven's current price could be inflated.

Exploring Other Perspectives

Biohaven’s Simply Wall St Community fair value estimates span US$2.23 to US$22.25 across 5 views, underlining how far opinions diverge. Set that against the company’s very short cash runway and heavy losses, and you can see why broader expectations for execution and funding are so critical to its future path.

Explore 5 other fair value estimates on Biohaven - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Biohaven research is our analysis highlighting 5 important warning signs that could impact your investment decision.
• Our free Biohaven research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biohaven's overall financial health at a glance.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.